Search
Pargyline
go.drugbank.com/drugs/DB01626ApprovedPargyline is a monoamine oxidase inhibitor with antihypertensive properties.
Ferric subsulfate
go.drugbank.com/drugs/DB13885ApprovedFerric subsulfate is a stypic or hemostatic agent that causes agglutination of surface proteins resulting in local hemostasis. It has the chemical formula Fe4(OH)2(SO4)5. … It is used after superficial skin biopsies.
QR-333
go.drugbank.com/drugs/DB05533InvestigationalQR-333 is a concentrated and standardized nutrient based active compounds dosed in a topical cream designed to reduce oxidative stress and treat symptoms of Diabetic Peripheral Neuropathy, a nerve disorder
Solenopsis richteri
go.drugbank.com/drugs/DB11026ApprovedSolenopsis richteri allergenic extract is used in allergenic testing. It is extracted from the black imported fire ant which is native to South Amercia. … The species has also been introduced in North Amercia. When stung, the bites are characterized by sterile pustules that are surrounded by reddened swelling along with redness extending beyond.
EW-A-401
go.drugbank.com/drugs/DB05525InvestigationalThis specific transcription factor has been shown in animal studies to increase expression of the VEGF-A gene, and to promote the growth of new blood vessels. … EW-A-401 is a circle of genetic material (plasmid DNA) that instructs the body to produce a genetically-engineered transcription factor, a protein that regulates expression of genes.
TPI-ASM8
go.drugbank.com/drugs/DB05572InvestigationalTPI-ASM8 was under investigation in clinical trials NCT00822861, NCT01158898, NCT00402948, and NCT00550797, all for the treatment of Asthma.
Bezitramide
go.drugbank.com/drugs/DB01459ApprovedIllicitWithdrawnAfter cases of fatal overdose in the Netherlands in 2004 the drug was withdrawn from the market. Bezitramide has never been FDA approved and is currently a schedule II drug. … Bezitramide is a narcotic analgesic which was discovered in 1961, clinically tested around the 1970's [A14383], and marketed under the name Burgodin.
AZD3409
go.drugbank.com/drugs/DB04893ExperimentalAZD3409 is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. Phase I trials were initiated January 2003, and were ongoing as of February 2004.